The Path from Research to Treatment

Science at Syntrix is at the core of what we do, from the discovery of a promising therapeutic candidate to the preclinical and clinical research and development necessary to create a new medicine.

We are “technology agnostic” at Syntrix.  The starting point of all our research efforts is a significant medical need with the potential to develop a breakthrough therapy.  This approach may lead us to exploit a small molecule to attack the problem, or to use a biologic, like a protein or antibody.  Syntrix’s research efforts span a range of clinical needs.  We have particularly focused research programs in the medical areas that correspond to our clinical development programs – pain, pulmonary disease, and autoimmune inflammation. Our scientists are additionally investigating a small molecule solution for multi-resistant bacterial infections and the targeting of tumors through the folate receptor.  Our goal is to find treatments that can be used to treat multi-drug resistant bacterial infections and to specifically target tumors with a minimum of adverse effects to the patient.

A Collaborative Model

Syntrix relies on strong relationships to help us succeed in our mission of making a major impact on patients worldwide. We work with a wide variety of talented individuals and organizations around the globe in our research efforts, from academic researchers to innovative research organizations. Our researchers tap into a wide range of collaborative expertise both within the company and with external researchers, including those in the Seattle research community.

Many Sources of Inspiration

Our research programs originate from many sources.  Research inspiration can be as personal as a single scientist’s firsthand views and experience with a particular disease, or a new report in the scientific literature.  Avenues for new research can come from both internal and external discoveries.

Internal– Our researchers in medicinal chemistry make discoveries from the “ground up”,  creating new molecules with the potential to go all the way from the lab to the patient—such as the small molecule SX-682, now entering clinical development in oncology

External– Some of our greatest successes have been in realizing the potential of the discoveries of others, such as the brilliant late Dr. Barton Kamen, a pediatric oncologist and researcher at the University of Medicine and Dentistry of New Jersey.

We don’t limit ourselves to a set list of medical areas, and we’re always willing to venture in new directions. At Syntrix, an innovative entrepreneurial spirit in our researchers encourages them to pursue new avenues of research – while an integrative approach brings back together our remaining staff from throughout the company to focus our efforts on realistic end goals.